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100-Plat Myosin II Plays a Specific
Role in Driving Glioma Invasion of
Normal Brain
Christopher Beadle, Marcella Asanah, Pascale Monzo,
Richard Vallee, Peter Canoll, Steven Rosenfeld
Columbia University, New York, NY, USA.
The ability of gliomas to invade normal brain enormously limits the
efficacy of standard therapies. Targeting this invasive phenotype
requires understanding how glioma cells move and what intracellu-
lar machinery they use to invade normal brain. In normal brain,
glioma migration occurs in a two-step process that resembles how
neural and glial progenitor cells migrate in situ. These steps consist
of extension of a leading process, followed by forward propulsion of
the cell body. We show that forward propulsion of the cell body
requires the molecular motor myosin II when these cells have to
crawl through the mechanically-constrained 3-dimensional matrix
that characterizes the brain. By contrast, myosin II activity is
unnecessary when these tumor cells migrate on a 2-dimensional
surface in the absence of suchmechanical constraints. Immunoblots
and immunofluorescence reveal that tumors and their associated
vasculaturemarkedly up-regulatemyosin IIA expression, andRNAi
suppression of myosin IIA, but not myosin IIB, blocks tumor cell
invasion. Our results thus demonstrate thatmyosin IIA has a specific
and indispensable role in driving glioma invasion of normal brain,
presumably by providing internal compressive forces need to propel
the cell body and nucleus forward.




Anthony Kossiakoff1, Sachdev Sidhu2, Gabor Pal1
1University Chicago, Chicago, IL, USA
2Genentech, Inc., South San Francisco, CA, USA.
Protein-protein interactions are characterized by a striking structur-
al plasticity that allows contact points to adapt to conformational
changes and multiple amino acid substitutions. As a result, the
biophysics governing the steric and energetic properties of protein-
protein interactions is extremely complex. The structure-function
data base for human growth hormone (hGH) binding to its receptor
(hGHR) is probably the most extensive available for any large
protein-protein interface, but attempts to extract universal trends
have been hindered by the incompleteness of the data set. We have
developed combinatory techniques that have allowed us to access
the structural and functional effects of all possible point mutations
across the hGH-hGHR interface. This has allowed us to assess the
binding effects of introducing all 20 amino acid types in the 35
positions comprising the hGH binding interface. This has produced
the most comprehensive picture of adaptability in a large protein-
protein interface that has ever been achieved and has led to some
new and unexpected insights. We have determined that while there
are a few hot-spot residues that are immutable, at least half of the 35
residues can be simultaneously mutated to alaninewithout affecting
binding. Our data challenge the concept of conservative substitu-
tions, especially in the case for hydrophilic residues. Sequence
conservation across species is a poor predictor of functional impor-
tance. Hydrophobic residues in many instances can replace hydro-
philic ones even if that residue is involved in a specificH-bonding or
salt-bridge interaction. In a complementary phage display study, we
show that high affinity interactions can be achieved using a simple
binomial (Tyr, Ser) genetic code. This facilitates building high
affinity and specific interactions with a highly restricted chemical
diversity and demonstrates that conformational diversity trumps
sequence diversity in protein-protein interactions.
102-Symp Biophysics of Interactions
in Non-globular Proteins
Elizabeth Komives
University California, San Diego, La Jolla, CA, USA.
Protein-protein interactions mediated by non-globular proteins
generally involve more than one folded protein domain in the
interaction interface. Experimental results from two different inter-
actions will be discussed; the LRP1/apoE interaction and the NF-
kB/IkBa interaction. Isothermal titration calorimetry, SPR, NMR,
and amide H/D exchange results taken together help to understand
these interactions in more detail. In both of these cases, contribu-
tions to the energetics of the interaction come from more than one
“hot spot” and are energetically cumulative. In addition, the overall
favorable energy of interaction has a contribution from folding upon
binding. The functional significance in terms of binding to multiple
targets and binding kinetics will also be discussed.
103-SympUnderstandingProtein-ligand
Interactions: Correlating Structure and
Thermodynamics
John E. Ladbury
University College London, London, United Kingdom.
Isothermal titration calorimetry (ITC) provides a direct method for
determining thermodynamic parameters associated with biomolec-
ular interactions. The understanding of the correlation between the
change in thermodynamic parameters for a binding event and the
perturbation in structure forms one cornerstone of biophysical
science. Clearly, if correlations can be defined then predictive
algorithms can be produced which will permit the calculation of
compound affinities directly from high resolution structural data
(and vice versa). This would have dramatic effects on the temporally
and financially expensive processes associated with compound
development in the pharmaceutical industry. Although significant
effort has been made in this area, particularly in the last decade, the
application of these principles to drug development is fraught with
inconsistencies and inaccuracies. The SCORPIO database (www.
biochem.ucl.ac.uk/scorpio/scorpio.html) provides a repository for
thermodynamic data derived solely from ITC and thus is not prone
to potential problems in derivation of the enthalpic (and hence
entropic) contributions to binding inherent in spectroscopic meth-
ods. Data from SCORPIO has been used to assess potential correla-
tions between thermodynamic parameters and structure. These
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correlations, or lack thereof, will be discussed with respect to
general protein ligand interactions and specifically in relation to
drug development. The use of calorimetrically determined thermo-
dynamic data input to decision making in drug development will be
demonstrated.
104-Symp Computational Prediction of
Ligand Binding Modes and Affinities
Johan Aqvist
University Uppsala, Uppsala, Sweden.
Computer simulation has become an increasingly powerful tool for
addressing problems in molecular recognition. Wewill discuss how
the combination of efficient docking procedures with subsequent
binding free energy calculations can be used to predict both binding
modes and affinities with good accuracy and, in particular, recent
results utilizing the linear interaction energy (LIE) method will be
presented. Wewill further address the problems of sensitivity to the
3D receptormodel, discrimination between right andwrong binding
modes, the reliability of empirical scoring functions as well as
mapping of key interactions for the recognition process. Examples
will include both enzyme-inhibitor and ion channel-blocker
complexes.
Symposium 6: EGF Receptor Signaling and Networks
105-Symp Extracellular control of
EGF receptor
Kate Ferguson
University Pennsylvania Sch Med, Philadelphia, PA, USA.
It is well accepted that the first step in the activation of receptor
tyrosine kinases (RTKs), such as those of the epidermal growth
factor receptor (EGFR) family, involves ligand-induced receptor
dimerization or alteration of a pre-existing dimers. X-ray crystal
structures of the extracellular region of EGFR (sEGFR) reveal an
unexpected mechanism for ligand-induced dimerization. All of the
contacts across the dimer interface in the sEGFRdimer aremediated
by the receptor, with the majority contributed by domain II. This
contrasts with the case for most other RTKs where the ligand is the
primary mediator of dimer contacts. In unliganded sEGFR the
domain II dimerization interface is occluded in an intramolecular
interaction with domain IV. Ligand binding promotes a dramatic
domain rearrangement in sEGFR, exposing and stabilizing the
domain II dimerization interface. This mechanism has substantial
implication for extracellular control of EGFR activation.
The EGFR family is implicated in several disease states,
perhaps most notably in many cancers. For example, EGFR
activation in epithelial tumors has been linked with more aggres-
sive disease and poorer outcomes. Drugs that inactivate EGFR
through interaction with either the extracellular or intracellular
regions of EGFR are under intense clinical investigation. The
structures of the antigen binding fragments from several thera-
peutic antibodies have been determined in complex with the
extracellular regions of EGFR family members. These structures
indicate several possible mechanisms of inhibition. The structure-
based models for EGFR activation suggest additional modes of
binding that may also be effective. Finally impact of activating
tumor mutations in evaluating the optimal mode of EGFR inhibi-
tion will be discussed.
106-Symp Structural and Mechanistic
Studies of Cancer-causing Mutations
in the EGFR Kinase Reveal A Novel
Mechanism of Drug Resistance
Michael Eck
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mutations in the EGFR kinase are a cause of non-small cell lung
cancer, and the presence of thesemutations correlates with response
to small-molecule tyrosine kinase inhibitors (TKIs). Interestingly,
some of the mutant kinases are as much as ~100-fold more potently
inhibited by gefitinib and erlotinib than thewild-type kinase, despite
the fact that these TKIs were developed to target the WT enzyme.
Structural studies reveal an altered binding mode of gefitinib in the
L858R mutant, which may in part explain its enhanced sensitivity.
Additionally, kinetic studies show that the L858R and other mutants
have diminished affinity for ATP, rendering them more sensitive to
these ATP-competitive TKIs. Although patients with tumors har-
boring a mutant EGFR initially respond to these drugs, longer-term
efficacy has been limited by the emergence of drug resistance, often
conferred by an additional mutation of Threonine 790 in the EGFR
toMethionine (T790M). This “gatekeeper”mutation lies in the ATP
binding pocket of the kinase, and has been thought to confer
resistance by sterically interfering with drug binding. However, we
show through binding studies, enzyme kinetics, and x-ray crystal-
lography that the T790M mutant and L858R/T7890M double
mutant retain low nanomolar affinity for gefitinib, and that the
T790M mutation does not alter the binding mode of the inhibitors.
Instead, clinically observed drug resistance is due to an increase in
the ATP affinity conferred by the T790M substitution. Since TKIs
must compete with ATP to achieve their intended effect, their
effective potency is diminished by the enhanced ATP-affinity. Thus
the T790M mutation is a “generic” resistance mutation that can be
expected to diminish the potency of any ATP-competitive inhibitor.
Irreversible inhibitors, as a class, overcome this effect through
covalent binding.
107-Symp Role of the Intracellular
Juxtamembrane Region in Activation of
the EGFR
Stuart McLaughlin
SUNY Stony Brook, Stony Brook, NY, USA.
The receptor tyrosine kinase EGFR has an extracellular ligand-
binding domain, a helical transmembrane (TM) domain linked to a
flexible, unfolded juxtamembrane (JM) region, and a kinase do-
main. A popular model of EGFR activation postulates ligand
binding induces dimer formation, permitting the C lobe of one
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